Induction of T-cell antitumor immunity and protection against tumor growth by secretion of soluble human CD70 molecules

Cancer Gene Therapy

Volumn 11, Issue 7, 2004, Pages 497-507

  Cormary, Carine ^a   Gonzalez, Ricardo ^a   Faye, Jean Charles ^a   Favre, Gilles ^a   Tilkin Mariamé, Anne Françoise ^a  

^a INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

Costimulatory molecules; Immunotherapy; Mammary adenocarcinoma; Soluble CD70

Indexed keywords

CD70 ANTIGEN; CELL MEMBRANE MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DNA MODIFICATION; DRUG ACTIVITY; FEMALE; FIBROBLAST; GENE CONSTRUCT; GENE EXPRESSION; GENE THERAPY; GENE VECTOR; GENETIC TRANSFECTION; GROWTH RATE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IN VITRO STUDY; MEMORY CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTECTION; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR CELL; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD70; CELL LINE; CELL LINE, TUMOR; CELL MEMBRANE; CELL PROLIFERATION; COCULTURE TECHNIQUES; CULTURE MEDIA, CONDITIONED; FEMALE; FIBROBLASTS; INJECTIONS; LYMPHOCYTE ACTIVATION; MAMMARY NEOPLASMS, ANIMAL; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; SPLEEN; T-LYMPHOCYTES; TRANSFECTION; TRANSPLANTATION, HOMOLOGOUS;

ANIMALIA; MUS MUSCULUS;

EID: 3142598882     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700708     Document Type: Article

References (34)

1. Liu Y, Linsley PS. Costimulation of T-cell growth. Curr Opin Immunol. 1992;4:265.
2. Robey E, Allison JP. T-cell activation: integration of signals from the antigen receptor and costimulatory molecules. Immunol Today. 1995;16:306.
3. Gimmi CD, Freeman GJ, Gribben JG, Gray G, Nadler LM. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci USA. 1993;90:6586.
4. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991.
5. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol. 2002;3:999.
6. Grangeon C, Cormary C, Douin-Echinard V, Favre G, Couderc B, Tilkin-Mariame AF. In vivo induction of antitumor immunity and protection against tumor growth by injection of CD154-expressing tumor cells. Cancer Gene Ther. 2002;9:282.
7. Cavallo F, Martin-Fontecha A, Bellone M, et al. Coexpression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. Eur J Immunol. 1995;25:1154.
8. Lorenz MG, Kantor JA, Schlom J, Hodge JW. Anti-tumor immunity elicited by a recombinant vaccinia virus expressing CD70 (CD27L). Hum Gene Ther. 1999;10:1095.
9. Gravestein LA, Borst J. Tumor necrosis factor receptor family members in the immune system. Semin Immunol. 1998;10:423.
10. Hintzen RQ, Lens SM, Beckmann MP, Goodwin RG, Lynch D, van Lier RA. Characterization of the human CD27 ligand, a novel member of the TNF gene family. J Immunol. 1994;152:1762.
11. Tesselaar K, Gravestein LA, Van Schijndel GM, Borst J, van Lier RA. Characterization of murine CD70, the ligand of the TNF receptor family member CD27. J Immunol. 1997;159:4959.
12. Tesselaar K, Xiao Y, Arens R, et al. Expression of the murine CD27 ligand CD70 in vitro and in vivo. J Immunol. 2003;170:33.
13. Lens SM, Tesselaar K, van Oers MH, van Lier RA. Control of lymphocyte function through CD27-CD70 interactions. Semin Immunol. 1998;10:491.
14. Yamada S, Shinozaki K, Agematsu K. Involvement of CD27/CD70 interactions in antigen-specific cytotoxic T-lymphocyte (CTL) activity by perforin-mediated cytotoxicity. Clin Exp Immunol. 2002;130:424.
15. Brown GR, Meek K, Nishioka Y, Thiele DL. CD27-CD27 ligand/CD70 interactions enhance alloantigen-induced proliferation and cytolytic activity in CD8+ T lymphocytes. J Immunol. 1995;154:3686.
16. Kelly JM, Darcy PK, Markby JL, et al. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat Immunol. 2002;3:83.
17. Hintzen RQ, De Jong R, Hack CE, et al. A soluble form of the human T cell differentiation antigen CD27 is released after triggering of the TCR/CD3 complex. J Immunol. 1991;147:29.
18. Loenen WA, De Vries E, Gravestein LA, Hintzen RQ, van Lier RA, Borst J. The CD27 membrane receptor, a lymphocyte-specific member of the nerve growth factor receptor family, gives rise to a soluble form by protein processing that does not involve receptor endocytosis. Eur J Immunol. 1992;22:447.
19. Wykes M, Poudrier J, Lindstedt R, Gray D. Regulation of cytoplasmic, surface and soluble forms of CD40 ligand in mouse B cells. Eur J Immunol. 1998;28:548.
20. Faas SJ, Giannoni MA, Mickle AP, et al. Primary structure and functional characterization of a soluble, alternatively spliced form of B7-1. J Immunol. 2000;164:6340.
21. Hirano A, Longo DL, Taub DD, et al. Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. Blood. 1999;93:2999.
22. Notter M, Willinger T, Erben U, Thiel E. Targeting of a B71 (CD80) immunoglobulin G fusion protein to acute myeloid leukemia blasts increases their costimulatory activity for autologous remission T cells. Blood. 2001;97:3138.
23. Singh NP, Yolcu ES, Taylor DD, et al. A novel approach to cancer immunotherapy: tumor cells decorated with CD80 generate effective antitumor immunity. Cancer Res. 2003;63:4067.
24. Couderc B, Zitvogel L, Douin-Echinard V, et al. Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells. Cancer Gene Ther. 1998;5:163.
25. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell. 1990;61:1303.
26. Douin-Echinard V, Bornes S, Rochaix P, et al. The expression of CD70 and CD80 by gene-transfected tumor cells induces an antitumor response depending on the MHC status. Cancer Gene Ther. 2000;7:1543.
27. Bousso P, Levraud JP, Kourilsky P, Abastado JP. The composition of a primary T cell response is largely determined by the timing of recruitment of individual T cell clones. J Exp Med. 1999;189:1591.
28. Nieland JD, Graus YF, Dortmans YE, Kremers BL, Kruisbeek AM. CD40 and CD70 co-stimulate a potent in vivo antitumor T cell response. J Immunother. 1998;21:225.
29. Braun-Falco M, Hallek M. Recombinant adeno-associated virus (rAAV) vector-mediated cotransduction of CD70 and CD80 into human malignant melanoma cells results in an additive T-cell response. Arch Dermatol Res. 2001;293:12.
30. Glick RP, Lichtor T, de Zoeten E, Deshmukh P, Cohen EP. Prolongation of survival of mice with glioma treated with semiallogeneic fibroblasts secreting interleukin-2. Neurosurgery. 1999;45:867.
31. Kim TS, Chung SW, Kim SH, Kang SN, Kang BY. Therapeutic anti-tumor response induced with epitope-pulsed fibroblasts genetically engineered for B71 expression and IFN-gamma secretion. Int J Cancer. 2000;87:427.
32. El-Shami KM, Tirosh B, Popovic D, et al. Induction of antitumor immunity by proteasome-inhibited syngeneic fibroblasts pulsed with a transfected TAA peptide. Int J Cancer. 2000;85:236.
33. Sobol RE, Shawler DL, Carson C, et al. Interleukin 2 gene therapy of colorectal carcinoma with autologous irradiated tumor cells and genetically engineered fibroblasts: a Phase I study. Clin Cancer Res. 1999;5:2359.
34. Smythe JA, Fink PD, Logan GJ, Lees J, Rowe PB, Alexander IE. Human fibroblasts transduced with CD80 or CD86 efficiently trans-costimulate CD4 + and CD8 + T lymphocytes in HLA-restricted reactions: implications for immune augmentation cancer therapy and autoimmunity. J Immunol. 1999;163:3239.